anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As an immune checkpoint inhibitor (ICI), tislelizumab is an anti-programmed cell death protein 1 (PD-1) drug. With the extensive application of ICIs, there is an ever-increasing proportion of immune-related adverse events (irAEs) in clinical settings, some of which may even be life-threatening. Herein, we present a patient with tislelizumab-induced adrenal crisis. The main clinical manifestation was recurrent syncope accompanied by high-grade fever. Timely identification and hormone replacement therapy helped the patient overcome the crisis well. Finally, the patient discontinued tislelizumab and switched to antibody-drug conjugate (ADC) therapy. We report this case to improve our understanding of this situation, identify this kind of disease, and prevent adrenal crisis in time. Eventually, limiting toxicities reduces the interruption of immunotherapy. Since irAEs are multisystem damage with more non-specific symptoms, except for oncologists, general practitioners who endorse the need for taking a holistic approach to the patient should play a vital role in the management of cancer treatment.
Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
Participants received Placebo (dextrose 5% water \[D5W\] for injection U.S.P or normal saline \[NS\]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs \[DMARDs\], or combination) throughout the double-blind treatment period.
Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. The importance of core stability for injury prevention and performance enhancement has been popularized during the past decades. Up to date, core muscle strengthening plays an important role in different prevention programs, such as the "FIFA 11 +". Football is considered a high-intensity intermittent sport requiring high levels of physical fitness related to the ability to perform powerful actions, with a varied range of activities that involve both breaking and propulsive forces as well as distinct contraction modes and velocities. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. Kicking is one of the most fundamental and frequently used skills in soccer and its motion consists of several stages as follows: (1) the withdrawal of the thigh and shank (backswing); (2) the forward rotation of the thigh and shank, which occurs as a result of hip flexion; (3) the reduction of thigh angular velocity, with a corresponding increase in shank angular velocity up to impact with the ball; and (4) the follow-through. Football is seen as highly intensive sport with an increased injury rate. In adolescent football players, muscle-tendon unit adaptation is effecting by athletic performance. The mechanic loading on this unit results increase risk of lower extremity injuries. In the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.The aim of this study was to evaluate the effectiveness of core stabilization exercise program on adolescent male football players.
OBJECTIVES: Adult-onset idiopathic laryngeal dystonia (LD) can be associated with the risk of spread to muscles in the body. Subjects with extralaryngeal onset of dystonia have exhibited spread to the larynx. Previous studies analyze the spread of other dystonias but emphasis has not been placed on LD. The objective was to identify demographic and clinical factors contributing to the spread of dystonia to and from the larynx.
METHODS: Data were obtained from the Dystonia Coalition (DC)-patients from 49 international clinical centers. Clinical and demographic data was taken from 143 out of 409 patients with diagnosed LD. Patient criteria included adult-onset LD diagnosed on exam with no co-morbid neurologic conditions and no dystonia in other locations.
RESULTS: Among the 143 patients, 94 (65.7%) patients were diagnosed with focal laryngeal onset, with the remainder having extralaryngeal onset. Family history and age at study were statistically significant indicators of a patient developing laryngeal versus extralaryngeal onset of dystonia. Among the laryngeal onset group, 21 cases (22.3%) had an average time of 5.81 ± 5.79 years to spread from diagnosis, most commonly to neck (61.9%). Among extralaryngeal onset patients, mean time of larynx spread was 7.92 ± 7.737 years, most commonly to neck (22.7%).
CONCLUSIONS: Our data indicates approximately a quarter of patients with laryngeal-onset dystonia will exhibit spread. There were no demographic or clinical factors that were statistically predictive of the likelihood of spread from larynx. Patients with dystonia elsewhere in the body should be counseled on the possibility of spread to larynx, and vice versa.
LEVEL OF EVIDENCE: 4 Laryngoscope, 134:2295-2299, 2024.
BACKGROUND: Gait imbalance has been reported in overweight individuals and could further impair their mobility and quality of life. As the feet are the most distal part of the body and sensitively interface with external surroundings, evaluating the plantar pressure distribution can provide critical insights into their roles in regulating gait balance control. Therefore, the purpose of this study was to evaluate the effect of body weight and different gait speeds on the plantar pressure distribution and whole-body center of mass (COM) motion during walking.
METHODS: Eleven overweight individuals (OB) and 13 non-overweight individuals (NB) walked on a 10-meter walkway at three speed conditions (preferred, 80% and 120% of preferred speed). Gait balance was quantified by the mediolateral COM sway. Plantar pressure data were obtained using wireless pressure-sensing insoles that were inserted into a pair of running shoes. Analysis of variance models were used to examine the effect of body size, gait speeds, or their interactions on peak mediolateral COM and peak plantar pressure during walking.
RESULTS: Significant group effects of peak plantar pressure under the lateral forefoot (P = 0.03), lateral midfoot (P = 0.02), and medial heel (P = 0.02) were observed. However, the mediolateral COM motion and spatiotemporal gait parameters only revealed significant speed effects.
SIGNIFICANCE: Findings from this study indicated that overweight individuals exhibited increased plantar pressure under the lateral aspect of the foot, particularly during the late stance phase of walking, in an effort to maintain a comparable mediolateral COM motion to that of non-overweight individuals. Such elevated pressure in overweight individuals may potentially increase the risk of musculoskeletal pathology in the long term. The identified patterns are noteworthy as they have practical implications for designing targeted interventions and improving the overall health of individuals with a high BMI.
842,965. Applying liquid medicaments. MILLIGAN, G. J. Oct. 7, 1958 [Oct. 15, 1957], No. 31986/58. Class 81(2). [Also in Group XXIII] An applicator for the treatment of small defined or hard-to-reach regions with a liquid medicament, particularly a dentin desensitizing or tooth protecting liquid, comprising a length 10 of bendable translucent, capillary tube, preferably formed of polyethylene, and a wick 15 protruding from one end 11 of the tube for conducting the liquid contents 14 of the tube through the protruding end of the wick, the other end 12 of the tube being adapted to be opened before use, e.g. by removing the plug 13 or by snipping off the end 12 if it is seal-welded (not shown), so as to expose the bore of the tube to atmosphere. The wick is preferably protected by a cap 16 and the bore of the tube 10 has a preferred diameter of about 2 mm.
PURPOSE:Wax for removal of hair having hair removing ability not inferior to rosin wax, having high safety, containing 5C petroleum resin. CONSTITUTION:Wax for removal of hair containing 5c pertroleum resin (e.g., polyisoprene, etc.). The 5C petrolum resin is a resin obtained by polymerizing 5C fraction prepared by cracking of naphtha, etc., namely, one or more unsaturated hydrocarbons comprising cyclopentadiene, etc. as main components, Kuinton (Nippon Zeon K.K.), Takiroru (Sumitomo Kagaku K.K.), etc. as the 5C petroleum resin are on the market. The 5C petroleum resin has high safety, and has hair removing ability not inferior to rosin wax. The replacement of rosin in existing wax composition for removal of hair with the 5C petroleum resin improves safety. In the operation, an amount of the 5C petroleum resin blended is preferably 60-85wt% based on the composition.
The aims were (i) to determine the effects of Cognitive behavioral therapy for insomnia (CBT-I) on sleep disturbances, pain intensity and disability in patients with chronic musculoskeletal pain (CMP), and (ii) to determine the dose-response association between CBT-I dose (total minutes) and improvements in sleep disorders, pain intensity and disability in patients with CMP. A comprehensive search was conducted in PubMed/MEDLINE, Web of Science, CINAHL, and SCOPUS until December 17, 2023. Randomized clinical trials (RCTs) using CBT-I without co-interventions in people with CMP and sleep disorders were eligible. Two reviewers independently extracted data and assessed risk of bias and certainty of the evidence. A random effects meta-analysis was applied to determine the effects on the variables of interest. The dose-response association was assessed using a restricted cubic spline model. Eleven RCTs (n = 1801 participants) were included. We found a significant effect in favor of CBT-I for insomnia (SMD: -1.34; 95%CI: -2.12 to -0.56), with a peak effect size at 450 min of CBT-I (-1.65, 95%CI: -1.89 to -1.40). A non-significant effect was found for pain intensity. A meta-analysis of disability was not possible due to the lack of data. This review found benefits of CBT-I for insomnia compared to control interventions, with a large effect size. In addition, it was estimated that a 250-min dose of CBT-I had a large effect on reducing insomnia and that the peak effect was reached at 450 min. These novel findings may guide clinicians in optimizing the use of CBT-I in people with CMP and insomnia.
Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.
Cumulative data suggest that neuroinflammation plays a prominent role in amyotrophic lateral sclerosis (ALS) pathogenesis. The purpose of this work was to assess if patients with ALS present a specific peripheral cytokine profile and if it correlates with neurological disability assessed by ALSFRS-R, the rate of disease progression, and the pattern of disease progression (horizontal spreading [HSP] versus vertical spreading [VSP]). We determined the levels of 15 cytokines in the blood of 59 patients with ALS and 40 controls. We identified a positive correlation between levels of pro-inflammatory cytokines (interleukin [IL]-17F, IL-33, IL-31) and the age of ALS patients, as well as a positive correlation between IL-12p/70 and survival from ALS onset and ALS diagnosis. Additionally, there was a positive correlation between the ALSFRS-R score in the upper limb and respiratory domain and IL-5 levels. In our ALS cohort, the spreading pattern was 42% horizontal and 58% vertical, with patients with VSP showing a faster rate of ALS progression. Furthermore, we identified a negative correlation between IL-5 levels and the rate of disease progression, as well as a positive correlation between IL-5 and HSP of ALS. To the best of our knowledge, this is the first study reporting a "protective" role of IL-5 in ALS.
NEW MATERIAL:A compound expressed by the formula showing the following physicochemical properties: Appearance, white powder; molecular weight, 362; molecular formula, C21H30O5; melting point, 248-250 deg.C; specific rotation, [alpha]D=+41.4 deg.; EI mass spectrum, m/z=362, etc. USE:A producing intermediate of progesterone derivative having corpus luteum hormone activity such as ovulation inhibiting action. PREPARATION:Acremonium strictum NN 106 strain (FERM P-9143) is subjected to shake culture in a culture medium. After the cultivation, liquid obtained by dissolving 4-pregnene-3,20-dione which is used as a substrate in DMF is added to the above-mentioned culture medium and the mixture is subjected to reaction. After the reaction solid content and germ cell ingredient are removed and then the resultant supernatant is extracted with ethyl acetate and the solvent ingredient is removed to provide a crude by purified fraction, which is then subjected to chromatography treatment.
Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
The present invention relates to sugar reduction soybean curd which belongs to the technical field of medicinal food processing. The sugar reduction soybean curd is characterized in that kochia scoparia components of sugar reduction medicinal plants are contained in the soybean curd, the kochia scoparia in the soybean curd can be juice of kochia scoparia leaves and stems, kochia scoparia leaves or kochia scoparia stems, and the sugar reduction soybean curd can also be in a dry soybean curd state. The present invention can make soybean curd products maintain original smooth and tender flavor of soybean curd, the nutritious value of the soybean curd is improved, and the soybean curd has a beautiful color. Sugar reduction components of the kochia scoparia, the kochia scoparia leaves and the kochia scoparia stems added can effectively reduce blood sugar in bodies of diabetics. The product of the present invention has the advantages of simple preparation method, low medicinal material price, easy medicinal material acquisition, low manufacture cost, no toxic side effect and general longtime application. The product of the present invention has an unambiguous therapeutical action on diabetic blood sugar reduction and a health care function.
The invention relates to a dihydrooxazole antibiotic with a chemical formula of C10H11NO3. The chemical structural formula of the dihydrooxazole antibiotic is shown in a formula (I) which is described in the specification. The invention further relates to a biosynthetic method and two chemical synthetic methods for the compound, i.e., dihydrooxazole antibiotic. Moreover, the invention also relates to application of the compound in inhibition of a plurality of human and animal pathogenic bacteria and crop pathogenic bacteria. The compound is a novel compound having not been reported at home and abroad and has a brand new molecular structure. The compound can be prepared both through microbial fermentation and artificial chemical synthesis.
Colorectal polyps are precursors of colorectal cancer. Metabolic dysfunction associated steatohepatitis (MASH) is one of metabolic dysfunction associated fatty liver disease (MAFLD) phenotypic manifestations. Much evidence has suggested an association between MASH and polyps. This study investigated the biomarkers of MASH and colorectal polyps, and the prediction of targeted drugs using an integrated bioinformatics analysis method. Differentially expressed genes (DEGs) analysis and weighted gene co-expression network analysis (WGCNA) were performed on GSE89632 and GSE41258 datasets, 49 shared genes revealed after intersection. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses depicted they were mainly enriched in apoptosis, proliferation and infection pathways. Machine learning algorithms identified S100P, FOXO1, and LPAR1 were biomarkers for colorectal polyps and MASH, ROC curve and violin plot showed ideal AUC and stable expression patterns in both the discovery and validation sets. GSEA analysis showed significant enrichment of bile acid and fatty acid pathways when grouped by the expression levels of the three candidate biomarkers. Immune infiltration analysis showed a significant infiltration of M0 macrophages and Treg cells in the colorectal polyps group. A total of 9 small molecule compounds were considered as potential chemoprevention agents in MASH and colorectal polyps by using the CMap website. Using integrated bioinformatics analysis, the molecular mechanism between MASH and colorectal polyps has been further explored.
The invention relates to a polypeptide and application thereof, in particular to a polypeptide for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis and application thereof. The amino acid sequence of the polypeptide for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis is selected from at least one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The polypeptide of the invention has activity which is equivalent to or better than HIP/PAP and can promote hepatocyte proliferation and/or inhibit hepatocyte apoptosis, and the polypeptide of the invention has the advantages of small molecular weight, easy synthesis, low immunogenicity and the like, so the polypeptide of the invention has wide application prospect.
Therapeutic compounds and compositions for the treatment of infectious diseases are disclosed. The compounds are xanthones and xanthone derivatives, such as 3,5-bis-epsi-(N,N-diethylamino)amyloxyxanthone. The described compositions include such compounds and a pharmaceutical carrier. These compositions also can include additional materials conventionally used to form therapeutic compositions. 3,5-bis-epsi-(N,N-diethylamino)amyloxyxanthone has an IC50 for Plasmodium falciparum of about 0.15 muM, and an IC50 for Leishmania mexicana of <<0.5 muM. These compositions are additionally useful for forming soluble complexes with heme and porphyrins.
Interleukin-17 (IL-17), a pivotal cytokine in immune regulation, has attracted significant attention in recent years due to its roles in various physiological and pathological processes. This review explores IL-17 in immunological context, emphasizing its structure, production, and signaling pathways. Specifically, we explore its involvement in inflammatory diseases and autoimmune diseases, with a notable focus on its emerging implications in cardiovascular system. Through an array of research insights, IL-17 displays multifaceted functions yet awaiting comprehensive discovery. Highlighting therapeutic avenues, we scrutinize the efficacy and clinical application of four marketed IL-17 mAbs along other targeted therapies, emphasizing their potential in immune-mediated disease management. Additionally, we discussed the novel IL-17D-CD93 axis, elucidating recent breakthroughs in their biological function and clinical implications, inviting prospects for transformative advancements in immunology and beyond.
Individuals forming modern societies along with technological developments are increasingly adopting sedentary lifestyle. This situation increases the risks in terms of morbidity and mortality. For this reason, especially all countries build their health policies on increasing physical activity and make strides to improve it. In order to reach the ideal physical activity level, the physical activity level should be evaluated. However, when the literature is evaluated, it is possible to come across different and many physical activity evaluation methods. This makes it difficult to compare. On the other hand, many researchers prefer to use scales and surveys because of their low costs and ease of use. Although there are many physical activity assessment scales in the literature based on age, gender, disorder or disease, social needs and other features, many of them cannot be used in our society because they are not Turkish. This poses an important obstacle for Turkish researchers to evaluate physical activity.

"The Active-Q: Physical Activity Questionnaire" is a web-based scale developed to investigate the absence of physical activity and activity for individuals over the age of 18. Individuals are asked to answer questions about their activity habits in the past year. By developing the scale, Bonn et al. Tested its validity and reliability comparatively with the 'Double labeled water' method and the accelerometer.

The investigators think that "The Active-Q: Physical Activity Questionnaire" will help physiotherapists and other health professionals in the field and in the field to evaluate individuals' physical activity by revealing their energy consumption values. Therefore, it was aimed to make this scale available to Turkish healthcare professionals by conducting the Turkish validity and reliability study.
A method for supporting a person afflicted with an anxiety disorder. The person afflicted with an anxiety disorder is provided with a first electronic communication device such as a cell phone, a smart phone, an iPhone, a laptop computer, or a special purpose custom device in operative communication with at least one trained counselor having access to a second electronic communication device. The counselor may be a member of a team of counselors. When an anxiety attack occurs, the afflicted person requests help via the first electronic communication device from the counselor to recover from the anxiety attack, the request for help including a goal. The afflicted person provides a set of options and chooses one option therefrom. The afflicted person then receives instruction from the counselor to take steps to recover, thus empowering the person afflicted with an anxiety disorder to problem solve for himself or herself.
Subjects will participate in two exposure sessions. The air pollution exposure consists of a 2-hour car ride along the NJ Turnpike. Samples will be collected at 3 time points for each exposure session: pre-exposure, immediately post-exposure, and 24 hours post-exposure. Blood samples will be collected immediately before and after a 5-minute occlusion at each time point. The subject will also be asked to provide samples of exhaled breath and complete symptom and stress questionnaires at each time point.

Blood samples will be analyzed for serum nitrite. Exhaled breath samples will be analyzed for nitrates and nitrites.